within Pharmacolibrary.Drugs.ATC.C;

model C10AA03
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.18,
    Cl             = 0.000225,
    adminDuration  = 600,
    adminMass      = 40 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.034,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.034499999999999996,
    Tlag           = 11.4,            
    Vdp             = 0.016,
    k12             = 16.8,
    k21             = 16.8
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>C10AA03</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Pravastatin is an HMG-CoA reductase inhibitor (statin) used to lower cholesterol and triglycerides in the blood, primarily to prevent cardiovascular disease. It is approved and widely used for the treatment of hypercholesterolemia and to reduce the risk of heart attack and stroke.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters observed in healthy adult volunteers after a single oral dose.</p><h4>References</h4><ol><li><p>Hu, Z, et al., &amp; Zhou, S (2005). Herb-drug interactions: a literature review. <i>Drugs</i> 65(9) 1239–1282. DOI:<a href=&quot;https://doi.org/10.2165/00003495-200565090-00005&quot;>10.2165/00003495-200565090-00005</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/15916450/&quot;>https://pubmed.ncbi.nlm.nih.gov/15916450</a></p></li><li><p>Kosoglou, T, et al., &amp; Alton, KB (2005). Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. <i>Clinical pharmacokinetics</i> 44(5) 467–494. DOI:<a href=&quot;https://doi.org/10.2165/00003088-200544050-00002&quot;>10.2165/00003088-200544050-00002</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/15871634/&quot;>https://pubmed.ncbi.nlm.nih.gov/15871634</a></p></li><li><p>Deng, S, et al., &amp; Li, YJ (2009). Effects of a concomitant single oral dose of rifampicin on the pharmacokinetics of pravastatin in a two-phase, randomized, single-blind, placebo-controlled, crossover study in healthy Chinese male subjects. <i>Clinical therapeutics</i> 31(6) 1256–1263. DOI:<a href=&quot;https://doi.org/10.1016/j.clinthera.2009.06.006&quot;>10.1016/j.clinthera.2009.06.006</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/19695392/&quot;>https://pubmed.ncbi.nlm.nih.gov/19695392</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end C10AA03;
